[go: up one dir, main page]

WO2001068129A3 - Adjuvant pour vaccins - Google Patents

Adjuvant pour vaccins Download PDF

Info

Publication number
WO2001068129A3
WO2001068129A3 PCT/EP2001/002866 EP0102866W WO0168129A3 WO 2001068129 A3 WO2001068129 A3 WO 2001068129A3 EP 0102866 W EP0102866 W EP 0102866W WO 0168129 A3 WO0168129 A3 WO 0168129A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
adjuvanted
vaccines
adjuvant
squalene
Prior art date
Application number
PCT/EP2001/002866
Other languages
German (de)
English (en)
Other versions
WO2001068129A2 (fr
Inventor
Michael Broker
Original Assignee
Chiron Behring Gmbh & Co
Michael Broker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Behring Gmbh & Co, Michael Broker filed Critical Chiron Behring Gmbh & Co
Priority to ES01931522T priority Critical patent/ES2398451T3/es
Priority to DK01931522.5T priority patent/DK1265633T3/da
Priority to US10/221,941 priority patent/US20040047882A1/en
Priority to AU2001258279A priority patent/AU2001258279A1/en
Priority to EP01931522A priority patent/EP1265633B1/fr
Priority to JP2001566693A priority patent/JP2003526676A/ja
Priority to CA002402935A priority patent/CA2402935A1/fr
Publication of WO2001068129A2 publication Critical patent/WO2001068129A2/fr
Publication of WO2001068129A3 publication Critical patent/WO2001068129A3/fr
Priority to US12/386,753 priority patent/US20090208523A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un vaccin comprenant un premier vaccin auquel a été additionnée une émulsion oléoaqueuse contenant 5 % de squalène, 0,5 % de Polysorbate 80 et 0,5 % de trioléate de sorbitane dans une solution aqueuse tampon de citrate de pH 6, 5. Ledit vaccin comprend un deuxième vaccin sans adjuvant, servant de partenaire de combinaison pour une utilisation simultanée, séparée, ou étalée dans le temps à des fins d'immunisation contre des maladies infectieuses d'origine virale, bactérienne ou parasitaire.
PCT/EP2001/002866 2000-03-14 2001-03-14 Adjuvant pour vaccins WO2001068129A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ES01931522T ES2398451T3 (es) 2000-03-14 2001-03-14 Coadyuvante para vacunas
DK01931522.5T DK1265633T3 (da) 2000-03-14 2001-03-14 Vaccineadjuvans
US10/221,941 US20040047882A1 (en) 2000-03-14 2001-03-14 Adjuvant for vaccines
AU2001258279A AU2001258279A1 (en) 2000-03-14 2001-03-14 Adjuvant for vaccines
EP01931522A EP1265633B1 (fr) 2000-03-14 2001-03-14 Adjuvant pour vaccins
JP2001566693A JP2003526676A (ja) 2000-03-14 2001-03-14 ワクチン用のアジュバント
CA002402935A CA2402935A1 (fr) 2000-03-14 2001-03-14 Adjuvant pour vaccins
US12/386,753 US20090208523A1 (en) 2000-03-14 2009-04-22 Adjuvant for vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10012370A DE10012370A1 (de) 2000-03-14 2000-03-14 Adjuvans für Vakzinen
DE10012370.8 2000-03-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/386,753 Continuation US20090208523A1 (en) 2000-03-14 2009-04-22 Adjuvant for vaccines

Publications (2)

Publication Number Publication Date
WO2001068129A2 WO2001068129A2 (fr) 2001-09-20
WO2001068129A3 true WO2001068129A3 (fr) 2002-03-14

Family

ID=7634665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/002866 WO2001068129A2 (fr) 2000-03-14 2001-03-14 Adjuvant pour vaccins

Country Status (11)

Country Link
US (2) US20040047882A1 (fr)
EP (1) EP1265633B1 (fr)
JP (1) JP2003526676A (fr)
AU (1) AU2001258279A1 (fr)
CA (1) CA2402935A1 (fr)
CY (1) CY1113826T1 (fr)
DE (1) DE10012370A1 (fr)
DK (1) DK1265633T3 (fr)
ES (1) ES2398451T3 (fr)
PT (1) PT1265633E (fr)
WO (1) WO2001068129A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528647A (ja) * 2003-07-24 2006-12-21 メリアル リミテッド 新規ワクチン製剤
WO2007110776A1 (fr) * 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Stockage de vaccins antigrippaux sans refrigeration
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
SI2032163T1 (sl) * 2006-06-15 2013-05-31 Novartis Ag Večodmerni režim za ceplenje proti influenci, pri katerem se privarčuje adjuvant
AU2007330494B2 (en) * 2006-12-06 2014-03-13 Seqirus UK Limited Vaccines including antigen from four strains of influenza virus
JP4938911B2 (ja) * 2008-08-28 2012-05-23 ノバルティス アーゲー 高度に生産する酵母からのスクアレンの生産
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
JP2013504556A (ja) 2009-09-10 2013-02-07 ノバルティス アーゲー 気道疾患に対する組み合わせワクチン
WO2011066390A2 (fr) * 2009-11-25 2011-06-03 Wildcat Discovery Technologies, Inc. Adjuvants de dimension nanométrique et compositions pharmaceutiques et procédés apparentés
CN107080838A (zh) 2010-06-04 2017-08-22 惠氏有限责任公司 疫苗制剂
NZ608362A (en) 2010-09-01 2015-11-27 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
AU2012222883A1 (en) 2011-03-02 2013-10-17 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
WO2013132041A2 (fr) 2012-03-08 2013-09-12 Novartis Ag Formulations à adjuvant de vaccins de rappel
CN102671194B (zh) * 2012-05-07 2013-08-14 成都康华生物制品有限公司 一种人用预防狂犬病和破伤风的疫苗
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
LT3506935T (lt) 2016-09-02 2024-04-25 Sanofi Pasteur, Inc. Vakcina nuo neisseria meningitidis
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR20200140238A (ko) 2018-01-02 2020-12-15 클로리스 바이오사이언시스 인코포레이티드 암에 대한 예방적 및 치료적 치료로서의 ipsc 기반 백신
TWI694254B (zh) * 2018-03-26 2020-05-21 國光生物科技股份有限公司 一種定量疫苗成品劑量方法及試組
CN110680798B (zh) * 2018-07-04 2024-02-09 辽宁成大生物股份有限公司 一种含佐剂mf59和芦荟提取物组合的肺炎多糖疫苗可溶性微针
CN110664749B (zh) * 2019-10-21 2021-07-30 上海市皮肤病医院 一种基于mf59包载抗原纳米乳及其制备方法和应用
BR112023023094A2 (pt) 2021-05-06 2024-02-06 Hipra Scient S L U Vacina de subunidade de sars-cov-2
BR112023023098A2 (pt) 2021-05-06 2024-01-30 Hipra Scient S L U Vacina de subunidade de sars-cov-2
EP4346886A1 (fr) 2021-06-01 2024-04-10 Khloris Biosciences, Inc. Vaccins contre le cancer à base de cellules souches pluripotentes induites
AU2022325896A1 (en) 2021-08-13 2024-02-22 Khloris Biosciences, Inc. Ipsc-based vaccine as a prophylactic and therapeutic treatment for cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021465A2 (fr) * 1995-01-12 1996-07-18 Connaught Laboratories Limited Molecules conjuguees immunogenes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05294845A (ja) * 1991-11-25 1993-11-09 Nisshin Oil Mills Ltd:The 免疫原組成物
JP4205172B2 (ja) * 1997-05-01 2009-01-07 プロテクション・アンリミテッド・インコーポレイテッド ワクチンアジュバントとしての神経成長因子
JP2002520299A (ja) * 1998-07-09 2002-07-09 メルク エンド カムパニー インコーポレーテッド ポリヌクレオチドワクチン配合物
WO2000006738A2 (fr) * 1998-07-27 2000-02-10 Microbial Technics Limited Acides nucleiques et proteines de streptococcus pneumoniae
NZ567978A (en) * 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021465A2 (fr) * 1995-01-12 1996-07-18 Connaught Laboratories Limited Molecules conjuguees immunogenes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D.M. GRANOFF ET AL.: "MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM 197 conjugate vaccine.", INFECTION AND IMMUNITY, vol. 65, no. 5, May 1997 (1997-05-01), WASHINGTON, US, pages 1710 - 1715, XP002181051 *
M. DUPUIS ET AL.: "Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice.", VACCINE, vol. 18, no. 5-6, 14 October 1999 (1999-10-14), GUILDFORD, GB, pages 434 - 439, XP002181052 *
S. DE DONATO ET AL.: "Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly.", VACCINE, vol. 17, 1999, GUILDFORD, GB, pages 3094 - 3101, XP002181050 *

Also Published As

Publication number Publication date
AU2001258279A1 (en) 2001-09-24
EP1265633A2 (fr) 2002-12-18
EP1265633B1 (fr) 2012-12-12
WO2001068129A2 (fr) 2001-09-20
DK1265633T3 (da) 2013-01-07
PT1265633E (pt) 2013-01-31
DE10012370A1 (de) 2001-09-27
ES2398451T3 (es) 2013-03-19
JP2003526676A (ja) 2003-09-09
US20040047882A1 (en) 2004-03-11
CA2402935A1 (fr) 2001-09-20
US20090208523A1 (en) 2009-08-20
CY1113826T1 (el) 2016-07-27

Similar Documents

Publication Publication Date Title
WO2001068129A3 (fr) Adjuvant pour vaccins
WO2003028632A3 (fr) Mise au point d'un vaccin preventif contre l'infection par filovirus chez les primates
DK0764029T3 (da) Proteinadjuvanser
WO2004030608A3 (fr) Vaccins sous forme de nanoemulsion
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
WO2003059381A3 (fr) Préparations immunogènes et vaccins à base d'arn
ATE270707T1 (de) Entepneumovirus und entsprechendes impfstoff
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
MY125202A (en) Vaccine
WO2006068663A3 (fr) Compositions de vaccin et procedes permettant de traiter des infections par coronavirus
MXPA03002453A (es) Uso de imidazoquinolinaminas como mejoradores de vacunacion de acido desoxirribonucleico.
DE60210456D1 (de) Solubisierung von kapseln polysacchariden
IL154913A0 (en) Composition comprising immunogenic microparticles
WO2003002065A3 (fr) Compositions de vaccin vhc e1e2
WO2001062283A3 (fr) Nouvelle formulation d'adjuvant des muqueuses, non antigenique, modulant l'effet de substances, y compris d'antigenes de vaccin, en contact avec les surfaces de muqueuses
WO2002087494A3 (fr) Nouveau vaccin
WO2003051288A3 (fr) Vaccin mycobacterien
WO2002009752A3 (fr) Composants et compositions d'adjuvants immunologiques et procedes d'utilisation de ceux-ci
SG159525A1 (en) Vaccine
WO2004058188A3 (fr) Compositions vaccinales et procedes
WO2002017961A1 (fr) Preparation d'un vaccin renfermant un acide gras comme compose
WO2002032455A3 (fr) Vaccin
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
WO2001064243A3 (fr) Utilisation de la proteine mic3 de toxoplasma gond11 en tant qu'agent immunogene
WO2004058806A3 (fr) Corps d'inclusion utilises comme antigenes dans la vaccination d'animaux

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 566693

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2402935

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001931522

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001931522

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10221941

Country of ref document: US